A Collection of Anti...
20th May 2020 Content supplied by: Sino Biological US Inc.
Bioreagents Related to SARS-CoV-2 (COVID-19) Vaccine Development
Sino Biological was the first to market with mammalian cell-made COVID-19 viral recombinant proteins and offers a full range of these and other bioreagents to complement and aid in COVID-19 vaccine development and has the world’s largest selection of coronavirus research-grade products.
To support the development of SARS-CoV-2 (COVID-19) Vaccine, on April 30, 2020, GeoVax Labs, Inc., a biotechnology company developing human vaccines and immunotherapies against infectious diseases and cancer, announced that Beijing- and Philadelphia-based Sino Biological, Inc. will be its exclusive supplier of SARS-CoV-2 (COVID-19) bioreagent research products.
Under the terms of the agreement, Sino Biological will provide key bioreagents such as recombinant proteins, antibodies and detection kits for use in COVID-19 vaccine development underway at GeoVax. Sino Biological will also obtain exclusive rights to research-use-only (RUO) reagents developed jointly by the companies.
Sino Biological is an international reagent supplier and service provider. The company specializes in recombinant antigen production and antibody development. The company’s ever-growing portfolio of products includes recombinant proteins, monoclonal antibodies, ELISA assay kits, expression clones, cell culture media, and other molecular biology tools.
The company also offers a variety of customized services, mainly focusing on recombinant production of antigens and antibodies. Sino Biological is dedicated to virology and infectious disease research. Its newly launched ProVir™ collection is the world’s largest viral antigen bank, carrying over 800 products from 350 strains of viruses.
Date Published: 20th May 2020
Source article link: View
A Collection of Antigens and